A 2-Part, Open-Label Trial to Evaluate the Pharmacokinetics of MK-3866 Following the Administration of a Single IV Dose to Subjects With Mild, Moderate, and Severe Renal Impairment and End Stage Renal Disease

Trial Profile

A 2-Part, Open-Label Trial to Evaluate the Pharmacokinetics of MK-3866 Following the Administration of a Single IV Dose to Subjects With Mild, Moderate, and Severe Renal Impairment and End Stage Renal Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs MK-3866 (Primary)
  • Indications Bacterial infections
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 25 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 23 Jan 2018 Planned primary completion date changed from 23 Feb 2018 to 5 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top